A better understanding of the #immunesystem is essential to avoiding another #pandemic. Learn more from our CEO and co-founder, @NoamSolomon1

🧬 Inside Immunai kicks off 2025 with Eva Macuchova, our Scientific Team Lead! At Immunai, she’s helped standardize data & fuel AI-powered discoveries in cancer & inflammatory research. Crime novel lover, foodie, & data expert—join her team!

Immunai has been named Startup of the Week via @theinnovator⭐️ Read how Immunai is bridging the gap between computer science and life sciences to combat Eroom’s Law—the rising costs of drug development.

Our CEO @NoamSolomon1 is headed to Davos to represent Immunai as part of the @WEF Unicorn Program with other high-growth companies shaping the future of their industries. Are you attending?

AI has massive potential in immunotherapies—so why is drug development still lagging? In @hitconsultant, our CEO, @NoamSolomon1 unpacks data gaps, immune system mapping, and how AI can transform the process. Read:

What drives progress in cancer treatment? At Immunai, it starts with the team above all. Healthy debate and shared commitment power our breakthroughs in immunology and beyond. Read more from @MichaBreakstone and @Inc:

95% of drugs fail before reaching patients. Our CEO @NoamSolomon1 joined @MaayanJaffe on @ILTVNews’s Lights of Hope panel to discuss how AI and our immune cell atlas are improving clinical trial efficiency and driving better outcomes.

🧬JPM season is here! Immunai’s co-founder & CEO, will be at JPM 2025 in January to discuss how AI and our single-cell multi-omics atlas are transforming immune system insights and early R&D. Will you be there? Let us know in the comments👇

The immune system holds valuable data for advancing medicine. Our work with @TevaUSA uses AI and our immune cell atlas to analyze patient responses, refine dosing, and identify biomarkers—helping move therapies forward. @TheCancerLetter

In drug development, every decision counts. As highlighted in @GenomeWeb by @abonislaw, our partnership with @TevaUSA is bringing immune profiling into earlier stages, unlocking new insights into autoimmune diseases

Honored to be named Immunology Innovation of the Year by the @BioTech_Awards! Our commitment to advancing immunology with AI can help pharma teams understand immune responses like never before.

We’re teaming up with @TevaUSA to bring precision to clinical trials in immunology & immuno-oncology. Using AMICA™ & IDE™, we’re improving trial decision-making by refining drug mechanisms, dose selection, and biomarker insights. More in @BiopharmaTrend

Inside each cell lies a unique story of immune response. On the Impact AI Podcast, our CEO @NoamSolomon1 spoke with @heatherdcouture about how our immune atlas leverages AI & single-cell genomics for precise drug discovery. Listen here:

🧬 We’re continuing our “Inside Immunai,” with @dave15o1, Director. David leads the team building the "ChatGPT of the immune system" and thrives on the rare "eureka" moments in tech. Fun fact: He’s also a big fan of ‘Soulsborne’🎮Want to work with David?

The reason drug approval rates are so low isn’t just because treatments are complex—it’s because every person’s immune system is different. With AI and our AMICA platform, we’re using immune data to guide more precise drug development. Read @PharmaVoice

CEO @NoamSolomon1's new byline in @PharmExec is out today on how AI is lowering barriers in cell therapy. By harnessing data, we’re driving down costs and making these advanced treatments more accessible. Read it here:

Proud to enter a multi-year partnership with AstraZeneca to optimize clinical trials in oncology. Using our AI-powered platforms, we’re working together to bring new therapies to patients faster and more efficiently.

Thank you @shikha_nayar !

Our CEO, @NoamSolomon1, hosted @RuthReader at our NY office to discuss how AI is reshaping drug discovery. Featured in @politico, their conversation highlights our work in mapping the immune system to understand and predict how therapies will perform:

Immunai’s latest research in @AACR used high-throughput single-cell RNA sequencing to uncover key insights into pleural mesothelioma, including 4 gene programs and a new therapeutic target. Read more: